Interleukin-1 antagonism in type 1 diabetes of recent onset: Two multicentre, randomised, double-blind, placebo-controlled trials

The Lancet

Volumn 381, Issue 9881, 2013, Pages 1905-1915

  Moran, Antoinette ^a   Bundy, Brian ^b   Becker, Dorothy J ^c   DiMeglio, Linda A ^d   Gitelman, Stephen E ^e   Goland, Robin ^f   Greenbaum, Carla J ^g   Herold, Kevan C ^h   Marks, Jennifer B ⁱ   Raskin, Philip ^j   Sanda, Srinath ^g   Schatz, Desmond ^k   Wherrett, Diane K ^l   Wilson, Darrell M ^m   Krischer, Jeffrey P ^b   Skyler, Jay S ⁿ   Pickersgill, Linda ^o   De Koning, Eelco ^p   Ziegler, Anette G ^q   Böehm, Bernhard ^r   Badenhoop, Klaus ^s   Schloot, Nanette ^t   Bak, Jens Friis ^u   Pozzilli, Paolo ^v   Mauricio, Didac ^w   Donath, Marc Y ^x   Castaño, Luis ^y   Wägner, Ana ^z   Lervang, Hans Henrik ^aa   Perrild, Hans ^ab   Mandrup Poulsen, Thomas ^ac   more..

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Howard Hughes Medical Institute   (United States)

^g BENAROYA RESEARCH INSTITUTE   (United States)

^h YALE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF MIAMI   (United States)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k UNIVERSITY OF FLORIDA   (United States)

^l HOSPITAL FOR SICK CHILDREN   (Canada)

^m STANFORD UNIVERSITY   (United States)

ⁿ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^o STENO DIABETES CENTER   (Denmark)

^p LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^q TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^r UNIVERSITY OF ULM   (Germany)

^s GOETHE UNIVERSITY   (Germany)

^t LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^u AARHUS UNIVERSITY HOSPITAL   (Denmark)

^v UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^w HOSPITAL ARNAU DE VILANOVA   (Spain)

^x UNIVERSITY HOSPITAL BASEL   (Switzerland)

^y HOSPITAL DE CRUCES   (Spain)

^z HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^aa AALBORG UNIVERSITY HOSPITAL   (Denmark)

^ab BISPEBJERG HOSPITAL   (Denmark)

^ac UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CANAKINUMAB; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; CANADA; CELL FUNCTION; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EUROPE; FEMALE; FLU LIKE SYNDROME; GLUCOSE TOLERANCE TEST; HUMAN; INFECTION; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PAIN; PANCREAS ISLET BETA CELL; PATIENT CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT;

EID: 84878300647     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60023-9     Document Type: Article

References (25)

1. Steele C, Hagopian WA, Gitelman S, et al. Insulin secretion in type 1 diabetes. Diabetes 2004; 53: 426-33.
2. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial: a randomised, controlled trial. Ann Intern Med 1998; 128: 517-23.
3. Steffes MW, Sibley S, Jackson M, Thomas W. Beta cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003; 26: 832-36.
4. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346: 1692-98.
5. Herold KC, Gitelman S, Greenbaum C, et al. Treatment of patients with new onset type 1 diabetes with a single course of ant-CD3 mAb teplizumab preserves insulin production for up to 5 years. Clin Immunol 2009; 132: 166-73.
6. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352: 2598-608.
7. Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010; 53: 614-23.
8. Orban T, Bundy B, Becker DJ, et al, for the Type 1 Diabetes TrialNet Abatacept Study Group. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 378: 412-19.
9. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al, for the Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361: 2143-52.
10. Mastrandrea L, Yu J, Behrens T, et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009; 32: 1244-49.
11. Mandrup-Poulsen T, Pickersgill LMS, Donath MY. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol 2010; 6: 158-66.
12. Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-60.
13. Sandler S, Andersson A, Hellerstrom C. Inhibitory effects of interleukin 1 on insulin secretion, insulin biosynthesis, and oxidative metabolism of isolated rat pancreatic islets. Endocrinology 1987; 121: 1424-31.
14. Spinas GA, Hansen BS, Linde S, et al. Interleukin 1 dose-dependently affects the biosynthesis of (pro)insulin in isolated rat islets of Langerhans. Diabetologia 1987; 30: 474-80.
15. Yamada K, Takane-Gyotoku N, Yuan X, Ichikawa E, Inada C, Nonaka K. Mouse islet cell lysis mediated by interleukin-1-induced Fas. Diabetologia 1996; 39: 1306-12.
16. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012; 11: 633-52.
17. Sanda S, Bollyky J, Standifer N, Nepom G, Hamerman JA, Greenbaum C. Short-term IL-1beta blockade reduces monocyte CD11b integrin expression in an IL-8 dependent fashion in patients with type 1 diabetes. Clin Immunol 2010; 136: 170-73.
18. Sumpter KM, Adhikari S, Grishman EK, White PC. Preliminary studies related to anti-interleukin-1β therapy in children with newly diagnosed type 1 diabetes. Pediatr Diabetes 2011; 7: 656-67.
19. Greenbaum CJ, Mandrup-Poulsen T, Friedenberg-McGee P, et al, for the Type 1 Diabetes TrialNet Research Group and the European C-peptide Trial Study Group. Randomized comparisons of the mixed meal tolerance test versus the glucagon stimulation test for the assessment of beta cell function in type 1 diabetes. Diabetes Care 2008; 31: 1966-71.
20. Ludvigsson J, Faresjo M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008; 359: 1909-20.
21. Wherrett DK, Bundy B, Becker DJ, et al, for the Type 1 Diabetes TrialNet GAD Study Group. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011; 378: 319-27.
22. Ludvigsson J, Krisky D, Casas R, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012; 366: 433-42.
23. Ablamunits V, Henegariu O, Bondo Hansen J, et al. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade. Diabetes 2012; 61: 145-54.
24. Kaizer EC, Glaser CL, Chaussabel D, Banchereau J, Pascual V, White P. Gene expression in peripheral blood mononuclear cells from children with diabetes. J Clin Endocrinol Metab 2007; 92: 3705-11.
25. Alkanani AK, Rewers M, Dong F, Waugh K, Gottlieb PA, Zipris D. Dysregulated toll like receptor induced interleukin-1β and interleukin-6 responses in subjects at risk for the development of type 1. Diabetes 2012; 61: 2525-33.